At 100 years of activity, Biofarm Bucharest inaugurates one of the most modern drug factories in Romania and launches Biofen Extra

Must Read

SeedBlink acquires Symbid, one of the world’s first investment crowdfunding platforms, in a European consolidation move

By rbj Speedlink, the European co-investment platform in tech startups, has announced it has completed the acquisition of Symbid, one...

Biofarm: innovation ambassador, during the first six months of the year, the Romanian company focused on launching new products in the CHC segment dedicated...

By rbj Biofarm (stock symbol BIO), one of the most important drug manufacturers in Romania, reports significant increases in the...

The Romanian firefighters are present in France to support the French forces who are fighting the climacteric flames

By rbj Two C-17 Globemaster III aircraft from the Multinational Strategic Transport Unit and a C-27J Spartan aircraft of the...

Catalin Vicol, CEO Biofarm Bucharest

By rbj
Biofarm, one of the most important drug manufacturers in Romania, reports positive developments for the preliminary results of 2021: turnover of 239 million lei and a net profit of 60 million lei, up 11% compared to 2020. In addition, Biofarm reported EBITDA of 82 million lei, up 10% compared to 2020.
“Innovation, the driving force behind Biofarm’s mission, is strongly reflected in the figures for 2021, a year marked by significant achievements in all areas. The main events that defined Biofarm in 2021 were: the celebration of 100 years of uninterrupted activity, the inauguration of one of the most modern drug factories in Romania and the launch of Biofen Extra, through which we activated one of the most important CHC categories in terms of business potential,” said Cătălin Vicol, General Manager of Biofarm.
In terms of sell-out (sales from pharmacies to patients), Biofarm finished last year on the second position in terms of volume, respectively on the fourth position in terms of value in the category of CHC (Consumer Health Care). The launch of Biofen Extra consolidates Biofarm’s position in the top companies in the CHC category by activating one of the most important CHC categories in Romania – pain management. Biofen Extra, an OTC (Over-the-Counter) drug indicated in the treatment of severe pain, became a value leader in the ibuprofen and paracetamol combination segment within the first 8 months of its launch.
At the end of 2021, in the CHC category, Biofarm is the volume leader in the reference markets of nine brands in the portfolio: Colebil, Triferment, Bixtonim, Sennalax, Carmol, Nervocalmin, Carbocit, Extravalerianic and Devaricid.
Constant investments to increase brand capital, especially for the main brands in Biofarm’s portfolio, were also an important pillar in 2021. Over the past year, the process of revitalizing the visual identity for 9 other brands in Biofarm’s portfolio was completed. Consistent resources have also been allocated to launch new 360-degree communication campaigns to increase notoriety and test rate for portfolio-focused focus brands.
Biofarm’s portfolio covers the most important therapeutic areas in the Consumer Healthcare division – digestive & metabolic, respiratory & ORL, cardiovascular & circulatory, nervous system, multivitamins, with over 20 representative brands.
Biofarm continues to invest in the future and make a significant contribution to the long-term development of the Romanian pharmaceutical industry.
The state-of-the-art manufacturing equipment/systems in the new production facility allow continuous process monitoring, thus ensuring the production of high-quality medicines that meet the most stringent requirements of European legislation.
With a usable area of over 10,000 square meters and an annual production flow of over 30 million commercial units of tablets and capsules and more than 10 million liquid products, the new Biofarm plant is in line with the company’s strategic objectives: developing the portfolio through line extensions or new product launches and expanding to external markets.
Biofarm® is one of the first Romanian producers of medicines and food supplements. For 100 years Biofarm® has been with the specialists in Romania in the race to find the best solutions for maintaining human health. Today, Biofarm® is one of the top 10 manufacturers on the Romanian pharmaceutical market, a dynamic and highly competitive market. Biofarm® has a competitive product portfolio covering 65 therapeutic areas and continuously invests in media, commercial and marketing campaigns to promote its own products.

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -
Latest News

SeedBlink acquires Symbid, one of the world’s first investment crowdfunding platforms, in a European consolidation move

By rbj Speedlink, the European co-investment platform in tech startups, has announced it has completed the acquisition of Symbid, one...

Biofarm: innovation ambassador, during the first six months of the year, the Romanian company focused on launching new products in the CHC segment dedicated...

By rbj Biofarm (stock symbol BIO), one of the most important drug manufacturers in Romania, reports significant increases in the first half of the year...

The Romanian firefighters are present in France to support the French forces who are fighting the climacteric flames

By rbj Two C-17 Globemaster III aircraft from the Multinational Strategic Transport Unit and a C-27J Spartan aircraft of the Romanian Air Force performed, on...

ROCA Industry announces that its subsidiary Bico Industries will take over the majority stake in the Lithuanian company SmartTech AG

By rbj ROCA Industry, the holding company that brings together the construction materials companies in the ROCA Investments portfolio, announces that its subsidiary Bico Industries...

Hungarians fear inflation, but also global recession. The opinion of the Central Bank of Budapest. Viktor Orban’s government expects inflation of 20% in 2022

By rbj Inflation could accelerate to around 20 percent in the coming months, said Barnabás Virág, vice president of Bank Magyar Nemzeti. According to the...
- Advertisement -

More Articles Like This

- Advertisement -